FDA approves label expansion of Alnylam’s Oxlumo for PH1

Oxlumo is indicated to treat primary hyperoxaluria type 1 to reduce the levels of urinary oxalate (UOx) and plasma oxalate (POx) in paediatric and adult patients. Credit: Marisa Howenstine on Unsplash.